X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs GLENMARK PHARMA - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD GLENMARK PHARMA WYETH LTD/
GLENMARK PHARMA
 
P/E (TTM) x 27.7 19.8 140.1% View Chart
P/BV x 5.3 3.5 154.6% View Chart
Dividend Yield % 1.3 0.3 419.5%  

Financials

 WYETH LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
GLENMARK PHARMA
Mar-18
WYETH LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,044930 112.3%   
Low Rs818517 158.1%   
Sales per share (Unadj.) Rs298.6322.6 92.5%  
Earnings per share (Unadj.) Rs57.228.5 200.9%  
Cash flow per share (Unadj.) Rs58.439.2 149.1%  
Dividends per share (Unadj.) Rs17.002.00 850.0%  
Dividend yield (eoy) %1.80.3 660.6%  
Book value per share (Unadj.) Rs249.5183.0 136.3%  
Shares outstanding (eoy) m22.72282.17 8.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.12.2 139.0%   
Avg P/E ratio x16.325.4 64.0%  
P/CF ratio (eoy) x15.918.5 86.3%  
Price / Book Value ratio x3.74.0 94.4%  
Dividend payout %29.77.0 423.1%   
Avg Mkt Cap Rs m21,157204,206 10.4%   
No. of employees `0000.513.7 3.6%   
Total wages/salary Rs m40018,718 2.1%   
Avg. sales/employee Rs Th13,787.46,636.8 207.7%   
Avg. wages/employee Rs Th813.01,364.7 59.6%   
Avg. net profit/employee Rs Th2,643.3586.1 451.0%   
INCOME DATA
Net Sales Rs m6,78391,031 7.5%  
Other income Rs m353914 38.6%   
Total revenues Rs m7,13691,945 7.8%   
Gross profit Rs m1,61716,154 10.0%  
Depreciation Rs m273,019 0.9%   
Interest Rs m62,856 0.2%   
Profit before tax Rs m1,93811,193 17.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6323,155 20.0%   
Profit after tax Rs m1,3018,039 16.2%  
Gross profit margin %23.817.7 134.4%  
Effective tax rate %32.628.2 115.8%   
Net profit margin %19.28.8 217.1%  
BALANCE SHEET DATA
Current assets Rs m6,98469,887 10.0%   
Current liabilities Rs m2,05632,879 6.3%   
Net working cap to sales %72.640.7 178.7%  
Current ratio x3.42.1 159.8%  
Inventory Days Days9981 121.9%  
Debtors Days Days2493 25.6%  
Net fixed assets Rs m24428,892 0.8%   
Share capital Rs m227282 80.5%   
"Free" reserves Rs m5,44151,353 10.6%   
Net worth Rs m5,66851,635 11.0%   
Long term debt Rs m2541,418 0.1%   
Total assets Rs m7,901125,954 6.3%  
Interest coverage x353.34.9 7,182.0%   
Debt to equity ratio x00.8 0.5%  
Sales to assets ratio x0.90.7 118.8%   
Return on assets %16.58.6 191.1%  
Return on equity %22.915.6 147.4%  
Return on capital %34.015.1 225.5%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1536,317 0.0%   
Fx outflow Rs m2,6779,720 27.5%   
Net fx Rs m-2,66226,598 -10.0%   
CASH FLOW
From Operations Rs m92316,481 5.6%  
From Investments Rs m317-10,133 -3.1%  
From Financial Activity Rs m-481-4,685 10.3%  
Net Cashflow Rs m7591,770 42.9%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 6.9 163.8%  
FIIs % 7.2 34.4 20.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 10.5 289.5%  
Shareholders   21,978 56,727 38.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   MERCK LTD  STERLING BIOTECH  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades 370 Points Up; Hero MotoCorp & Tata Motors Gain Over 5%(12:30 pm)

Stock markets in India are presently trading higher following the outcome of assembly polls announced on Tuesday.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WYETH LTD WITH

MARKET STATS